A recent study by Germany's Federal Institute for Public Health found that marijuana consumption among 12-17 year olds decreased from 6.7% to 6.1% following recreational cannabis legalization in April 2024, contradicting a key argument against such reforms. Concurrently, use among 18-25 year olds rose to 25.6%. This research, seen as bolstering the case for cannabis law reform, led to a nearly 6% increase in Curaleaf's stock price, demonstrating market sensitivity to regulatory developments and supporting data in the cannabis sector.
A study from Germany's Federal Institute for Public Health has provided a significant tailwind for the cannabis sector by challenging a key anti-legalization argument. The research indicates that following recreational legalization in April 2024, cannabis consumption among 12-to-17-year-olds fell from 6.7% to 6.1%, with regular use in this cohort also declining. This development directly catalyzed a nearly 6% rise in Curaleaf's (CURLF) share price, demonstrating the market's high sensitivity to favorable regulatory data, especially as it occurred while the S&P 500 was down 0.6%. The study did, however, note an increase in consumption among young adults aged 18 to 25, which rose from 23.3% to 25.6% between 2023 and 2025. The positive market reaction underscores the perception that such government-backed data could bolster the case for further cannabis law reform globally, benefiting publicly traded operators, although the article notes that Curaleaf was not recently identified as a top pick by one analyst team, suggesting a need to balance sector-wide news with company-specific analysis.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
